The contract research organization and the commercialization of scientific research

Social Studies of Science

Volumn 35, Issue 4, 2005, Pages 503-548

  Mirowski, Philip ^a,b   Van Horn, Robert ^b  

^a Economics and the History and Philosophy of Science ^*  (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Commercialization of science; Contract research organization; Ghost authorship; Globalization of research; Intellectual property; New economics of science

Indexed keywords

COMMERCIAL PHENOMENA; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; MEDICAL RESEARCH; REVIEW; UNITED STATES;

BIOMEDICAL RESEARCH; COMMERCE; CONTRACT SERVICES; DRUG INDUSTRY; HUMANS; UNITED STATES;

EID: 23944521327     PISSN: 03063127     EISSN: None     Source Type: Journal    
DOI: 10.1177/0306312705052103     Document Type: Review

References (143)

1. Abraham, John (2002) 'The Pharmaceutical Industry as a Political Player', Lancet 360(9344): 1498-502.
2. Abraham, John & Helen Smith (eds) (2003) Regulation of the Pharmaceutical Industry (London: Palgrave).
3. Agres, Ted (2003) 'The Cost of Commercializing Academic Research', The Scientist 17: 58-59.
4. Angell, Marcia & Arnold Relman (2002) 'Patents, Profits and American Medicine', Daedalus (Spring): 102-11.
5. Azoulay, Pierre (2002) 'Acquiring Knowledge Within and Across Firm Boundaries', Columbia University School of Business, Working Paper.
6. Azoulay, Pierre (2003) 'Agents of Embeddedness', Columbia University School of Business, Working Paper.
7. Baltimore, David (2003) 'On Over-Weighting the Bottom Line', Science 301: 1050-51.
8. Bekelman, Justin, Yan Li & Cary Gross (2003) 'Scope and Impact of Financial Conflicts of Interest in Biomedical Research', Journal of the American Medical Association 284: 454-65.
9. Berenson, Alex (2004) 'An Industry in Poor Health', New York Times (18 December): A1.
10. Bero, Lisa & D. Rennie (1996) 'Influences on the Quality of Public Drug Studies', International Journal of Technological Assessment in Health Care 12(2): 209-37.
11. Bhopal, R., J. Rankin, E. McColl, L. Thomas, E. Kaner et al. (1997) 'The Vexed Question of Authorship', British Medical Journal 314: 1009-12.
12. Biagioli, Mario & Peter Galison (eds) (2003) Scientific Authorship: Credit and Intellectual Property in Science (New York: Routledge).
13. Blumenthal, D., E. Campbell, N. Causino & K. Seashore Lewis (1996) 'Participation of Life-Science Faculty in Research Relationships with Industry', New England Journal of Medicine 335: 1734-39.
14. Bodenheimer, Thomas (2000) 'Uneasy Alliance - Clinical Investigators and the Pharmaceutical Industry', New England Journal of Medicine 342: 1539-44.
15. Bogdanich, Walt & Melody Petersen (2002) 'Science for Sale - Ad Agencies and Drug Companies Hand in Hand?', Bill Moyers Now available at 〈www.pbs.org/now/transcript/transcript144_full.html〉 (accessed 18 March 2005).
16. Bok, Derek (2002) Universities in the Marketplace: The Commercialization of Higher Education (Princeton, NJ: Princeton University Press).
17. Boyd, Elizabeth, Mildred Cho & Lisa Bero (2003) 'Financial Conflict-of-interest Policies in Clinical Research: Issues for Clinical Investigators', Academic Medicine 78: 769-74.
18. Boyle, James (ed.) (2003) 'The Public Domain', Law and Contemporary Problems 66(1/2).
19. Breitstein, Joanna (2001) 'World Watch: Protecting People Everywhere', Pharmaceutical Executive (December).
20. Brown, James Robert (2000) 'Privatizing the University', Science 290: 1701.
21. Business Wire (2002) 'PharmaLinkFHI to Present', 30 January.
22. Campbell, Eric, Brian R. Clarridge, Manjusha Gokhale, Lauren Birenbaum, Stephen Hilgartner et al. (2002) 'Data Withholding in Academic Genetics: Evidence from a National Survey', Journal of the American Medical Association 287: 473-80.
23. Campbell, Eric, Joel S. Weissman, Ernest Moy & David Blumenthal (2001) 'Status of Clinical Research in Academic Health Centers: Views from the Research Leadership', Journal of the American Medical Association 286: 800-06.
24. Cho, Mildred K., Roy Shohara, Anna Schissel & Drummond Rennie (2000) 'Policies on Faculty Conflict of Interest at US Universities', Journal of the American Medical Association 284: 2203-08.
25. Croissant, Jennifer & Sal Restivo (eds) (2001) Degrees of Compromise: Industrial Interests and Academic Values (Albany, NY: SUNY Press).
26. Daemmrich, Arthur (2004) Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC: University of North Carolina Press).
27. Datta, P. (2003) 'Are We Ready for Drug Trials on a Large Scale?', Financial Times (24 September).
28. David, Paul & Partha Dasgupta (1994) 'Towards a New Economics of Science', Research Policy 23: 487-521.
29. Davidoff, Frank, C.D. DeAngelis, J.M. Drazen, J. Hoey, L. Hojgaard et al. (2001) 'Sponsorship, Authorship and Accountability', New England Journal of Medicine 345: 825-27.
30. Davidson, R.A. (1986) 'Source of Funding and the Outcome of Clinical Trials', Journal of General Internal Medicine 1: 155-58.
31. Davies, Helen (2001) 'The Role of the Private Sector in Protecting Human Research Subjects: A CRO perspective', talk delivered to the Institute of Medicine on 21 August. Available at 〈www.acrohealth.org/policy/pdfs/testimony_082101.pdf〉 (accessed 18 March 2005).
32. Davies, Helen (2002) 'Role of Contract Research Organizations (CRO) in Protecting Human Subjects', talk delivered at the DIA 2002 Annual Meeting. Available at 〈www.quintiles.com/NR/rdonlyres/ eynjegbwzxe4gsp2huilgm5p7eym4z q3d7skncf7cpxr6g5c6zalzh65fgrxbpjdn7hoephi3vwkzon7e4tgupbas5a/ Helen_Davies_DIA2002.pdf〉 (accessed 18 March 2005).
33. DeYoung, Karen & Deborah Nelson (2000) 'Latin America is Ripe for Trials, and Fraud', Washington Post (21 December) (fifth of six-part series).
34. Dickerstein, Kay & Drummond Rennie (2003) 'Registering Clinical Trials', Journal of the American Medical Association 290: 516-23.
35. Drahos, Peter & John Braithwaite (2002) Information Feudalism (New York: New Press).
36. Drennan, Katherine (2002) 'Patient Recruitment: The Costly and Growing Bottleneck in Drug Development', Drug Discovery Today 7(3): 167-70.
37. Dreyfuss, Rachel, Diane Zimmerman & H. First (eds) (2001) Expanding the Boundaries of Intellectual Property (New York: Oxford University Press).
38. DuBois, William (2003) 'New Drug Research, the Extraterritorial Application of FDA Regulations, and the Need for International Cooperation', Vanderbilt Journal of Transnational Law 36: 161-207.
39. Eisenberg, Rebecca (2001) 'Bargaining over the Transfer of Proprietary Research Tools', in R. Dreyfuss, D. Zimmerman & H. First (eds), Expanding the Boundaries of Intellectual Property (NewYork: Oxford University Press): 223-50.
40. Eisenberg, Rebecca & Arti Rai (2003) 'Bayh-Dole Reform and the Progress of Biomedicine', Law and Contemporary Problems 56: 289-314.
41. Elliott, Carl (2002) 'Diary', London Review of Books (28 November): 36-37.
42. Enserink, Martin (1999) 'NIH Proposes Rules for Materials Exchange', Science 284 (28 May): 1445.
43. Etzkowitz, Henry (2002) MIT and the Rise of Entrepreneurial Science (London: Routledge).
44. Feinstein, Alvan (2003) 'Scholars, Investigators and Entrepreneurs', Perspectives in Biology and Medicine 46: 234-53.
45. Feldman, Maryanne, Albert Link & Donald Siegel (2002) The Economics of Science and Technology (Kluwer, Norwell).
46. Fisher, Morris (2003) 'Physicians and the Pharmaceutical Industry', Perspectives in Biology and Medicine 46: 254-72.
47. Flaherty, Mary P., Deborah Nelson & Joe Stephan (2000) 'The Body Hunters', Washington Post (18 December): Al (second of six-part series).
48. Flanagin, A., L. Carey, P. Fontanarosa, Stephanie G. Phillips, Brian P. Pace et al. (1998) 'Prevalence of Articles with Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals', Journal of the American Medical Association 280: 222-24.
49. Forster, David (2002) 'Independent Institutional Review Boards', Seton Hall Law Review 32: 513-23.
50. Friedberg, M., B. Saffran, T. Stinson, Wendy Nelson & Charles E. Bennett (1999) 'Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology', Journal of the American Medical Association 282: 1453-57.
51. FY 2003 President's Budget for Department of Health and Human Services (2002) 〈www.fda.gov/bbs/topics/ANWSERS/2002/ANS01135.html〉 (accessed 18 March 2005).
52. Gad, Shane C. (2003) The Selection and Use of Contract Research Organizations (London: Taylor & Francis).
53. Gelijns, Annetine & Samuel Their (2002) 'Medical Innovation and Institutional Interdependence', Journal of the American Medical Association 287: 72-78.
54. Getz, Kenneth & Annick de Bruin (2000) 'Breaking the Development Speed Barrier: Assessing Successful Practices of the Fastest Drug Development Companies', Drug Information Journal 34: 725-36.
55. Giombetti, Ric (2002) 'Suicide Science - Paxil's Friendly Ghostwriter?' (April 8). Available at 〈www.counterpunch.org〉 (accessed 18 March 2005).
56. Goliszek, Andrew (2003) In the Name of Science (New York: St Martin's).
57. Greenberg, Daniel (2001) Science, Money and Politics (Chicago, IL: University of Chicago Press).
58. Healy, David (2003) 'In the Grip of the Python: Conflicts at the University-Industry Interface', Science and Engineering Ethics 9: 59-71.
59. Healy, David & D. Cattell (2003) 'Interface between Authorship, Industry and Science in the Domain of Therapeutics', British Journal of Psychiatry 183: 22-27.
60. Hedgecoe, Adam & Paul Martin (2003) 'The Drugs Don't Work', Social Studies of Science 33(3): 327-64.
61. Heller, Michael & Rebecca Eisenberg (1998) 'Can Patents Deter Innovation? The Anticommons in Biomedical Research', Science 280: 698.
62. Hicks, Diana (1995) 'Published Papers, Tacit Competencies', Industrial and Corporate Change 4: 401-24.
63. Hope, Janet (2003) 'Intellectual Property and the Biotechnology Revolution', 〈http://rsss.anu.edu.au/~janeth/Law.html〉 (accessed 18 March 2005).
64. Horton, Richard (2002) 'The Hidden Research Paper', Journal of the American Medical Association 287: 2775-78.
65. Hughes, Graham (2002) 'Annual Review of Contract Research Organizations', European Pharmaceutical Contractor (Spring), available at 〈www.samedanltd.com/homepage/epc.htm〉 (accessed 18 March 2005).
66. Hughes, Sue (2002) 'Does the Pharmaceutical Industry Have Too Much Control Over Clinical Trials?', Heartwire (15 November).
67. Johnson, Erica (2003) 'Medical Ghostwriting', CBC Marketplace (Air Date 25 March). Available at 〉www.cbc.ca/consumers/market/files/health/ghostwriting〉.
68. Kahin, Brian (2001) 'The Expansion of the Patent System: Politics and Political Economy', First Monday 6(1). Available at 〉http://firstmonday.org/issues/issue6_1/kahin〉.
69. Kaitin, Kenneth & Joseph DiMasi (2000) 'Measuring the Pace of New Drug Development in the User Fee Era', Drug Information Journal 34: 673-80.
70. Kaitin, Kenneth & Elaine Healy (2000) 'The New Drug Approvals of 1996, 1997 and 1998', Drug Information Journal 34: 1-14.
71. Kessler, David (2001) A Question of Intent (New York: Public Affairs).
72. Kevles, Daniel (1994) 'Ananda Chakrabarty Wins a Patent', Historical Studies in the Physical and Biological Sciences 25: 111-36.
73. Kevles, Daniel (1998) 'Diamond v. Chakrabarty and Beyond: The Political Economy of Patenting Life', in Arnold Thackray (ed.), Private Science: Biotechnology and the Rise of the Molecular Sciences (Philadelphia, PA: University of Pennsylvania Press): 65-79.
74. Kjaergard, L. & B. Als-Nielsen (2002) 'Association between Competing Interests and Authors' Conclusion: Epidemiological Study of Randomized Clinical Trials in the BMJ', British Medical Journal 325: 249-52.
75. Krimsky, Sheldon (2003) Science in the Private Interest (Lanham, MD: Rowman & Littlefield).
76. Kunin, Stephen, Mark Nagumo, Brian Stanton, Linda S. Therkorn & Stephen Walsh (2002) 'Reach-through Claims in the Age of Biotechnology', American University Law Journal 51: 608-38.
77. Kupiec-Weglinski, J.W. (2003) 'Interactions between the Pharmaceutical Industry and Academia Revisited', Transplantation Proceedings 35: 1238-39.
78. Lemonick, Michael & Andrew Goldstein (2000) 'At Your Own Risk', Time (22 April): 46-56.
79. Leonard, Thomas C. (2004) 'Making Betty Crocker Assume the Position', Journal of the History of Economic Thought 26: 115-22.
80. Lessig, Larry (2001) The Future of Ideas (New York: Basic).
81. Lester, David & Jane Connor (2003) 'New Tools for Clinical Practice', American Pharmaceutical Outsourcing (May/June). Available at 〈www.americanpharmaceuticaloutsourcing.com/articles〉.
82. Lexchin, Joel, Lisa Bero, Benjamin Djulbegovic & Otavio Clark (2003) 'Pharmaceutical Industry Sponsorship and Research Outcome and Quality', British Medical Journal 326: 1167-77.
83. McSherry, Corynne (2001) Who Owns Academic Work? (Cambridge, MA: Harvard University Press).
84. Magnus, David, Arthur Caplan & Glenn McGee (eds) (2002) Who Owns Life? (Amherst, MA: Prometheus).
85. Marks, Harry (1997) The Progress of Experiment (New York: Cambridge University Press).
86. Marshall, Elliot (1997) 'Need a Reagent? Just Sign Here ... ', Science 278: 212-13.
87. Maurer, Stephen (2002) 'Promoting and Disseminating Knowledge: The Public/Private Interface', Paper presented to NRC Symposium on Information in the Public Domain. Washington (September).
88. Meier, Barry (2004) 'Group is Said to Seek Full Drug-Trial Disclosure', New York Times (June 14): A1.
89. Milne, C. & C. Paquette (2004) 'Meeting the Challenge of the Evolving R&D Paradigm: What Role for the CRO?', American Pharmaceutical Outsourcing. Available at 〈www.americanpharmaceuticaloutsourcing.com〉.
90. Mirowski, Philip (2001) 'Re-engineering Scientific Credit in the Era of the Globalized Information Economy', First Monday (December), 〈www.firstmonday.dk/issues/issue6_12〉.
91. Mirowski, Philip (2004a) The Effortless Economy of Science? (Durham, NC: Duke University Press).
92. Mirowski, Philip (2004b) 'The Scientific Dimensions of Social Knowledge', Studies in the History and Philosophy of Science 35: 283-326.
93. Mirowski, Philip & Esther-Mirjam Sent (eds) (2002) Science Bought and Sold (Chicago, IL: University of Chicago Press).
94. Morgan, Steve, Morris Barer & Roberts Evans (2000) 'Health Economics Meets the Fourth Tempter: Drug Dependency and Scientific Discourse', Health Economics 9: 659-67.
95. Mowatt, Graham, Liz Shirran, Jeremy M. Grimshaw, Drummond Rennie, Annette Flanagin et al. (2002) 'Prevalence of Honorary and Ghost Authorship in Cochrane Reviews', Journal of the American Medical Association 287: 2769-71.
96. Nelson, Richard (2001) 'Observations on the Post Bayh-Dole Rise of Patenting at American Universities', Journal of Technology Transfer 26: 13-19.
97. Newfield, Christopher (2003) Ivy and Industry (Durham, NC: Duke University Press).
98. Newman, Nathan (2002) 'Big Pharma, Bad Science', Nation (25 July), available at 〈www.thenation.com/doc.mhtml%3Fi=20020805&s=newman20020725〉 (accessed 18 March 2005).
99. Nightingale, Paul & Paul Martin (2004) 'The Myth of the Biotech Revolution', Trends in Biotechnology 22: 564-69.
100. Nowotny, Helga, Peter Scott & Michael Gibbons (2001) Rethinking Science (Cambridge: Polity Press).
101. Okie, Susan (2001) 'Missing Data on Celebrex: Full Study Altered Picture of Drug', Washington Post (5 August): A11.
102. Olivieri, Nancy (2003) 'Patients Health or Company Profits?', Science and Engineering Ethics 9: 29-41.
103. Owen-Smith, Jason & Walter Powell (2003) "The Expanding Role of Patenting in the Life Sciences', Research Policy 32(9): 1695-711.
104. Parexel (2003) Pharmaceutical R&D Statistical Sourcebook (Waltham, MA: Parexel International).
105. Pear, Robert (2003) 'Congress Weighs Drug Comparisons', New York Times (24 August).
106. Pichaud, B.S. (2002) 'Outsourcing in the Pharmaceutical Manufacturing Process: an Examination of CRO Experience', Technovation 22: 81-90.
107. Pollack, Andrew (2002) 'Despite Billions for Discoveries, Pipeline of Drugs is Far from Full', New York Times (19 April).
108. Pollack, Andrew (2003) 'Three Universities Join Researcher to Develop Drugs', NewYork Times (31 July): C1.
109. Pollack, Andrew (2004) 'Is Biotechnology Losing its Nerve?', New York Times (February 27): Section 3: 1.
110. Pomfret, John & Deborah Nelson (2000) 'In Rural China, a Genetic Mother Lode', Washington Post (20 December) (fourth of six-part series).
111. Posner, Richard A. (2002) 'The Law & Economics of Intellectual Property', Daedalus (Spring): 5-12.
112. Press, Eyal & Jennifer Washburn (2000) 'The Kept University', Atlantic Monthly 285 (3): 39-54.
113. Psaty, Bruce & Drummond Rennie (2003) 'Stopping Medical Research to Save Money', Journal of the American Medical Association 289: 2128-30.
114. Public Citizen Health Research Group (2001) 'Rx R&D Myths: The Case Against the Drug Industry's R&D "Scare Card"'. Available at 〈www.citizen.org/hrg〉 (accessed 18 March 2005).
115. Rasmussen, Nicolas (2002) 'Of Small Men, Big Science, and Bigger Business: The Second World War and Biomedical Research in the US', Minerva 40: 115-46.
116. Rasmussen, Nicolas (2004) 'The Moral Economy of the Drug Company-Medical Scientist Collaboration in Interwar America', Social Studies of Science 34(2): 161-86.
117. Rasmussen, Nicolas (2005) 'The Commercial Clinical Trial in Interwar America: Three Types of Physician Collaborator', Bulletin for the History of Medicine (In the Press).
118. Reimers, Niels (1998) 'Stanford's Office of Technology Licensing and the Cohen/Boyer Cloning Patents', Oral History (Bancroft Library), Berkeley, CA.
119. Rennie, Drummond, Annette Flanagin & Veronica Yank (2000) 'The Contributions of Authors', Journal of the American Medical Association 284: 89-91.
120. Rettig, Richard (2000) 'Drug Research and Development: The Industrialization of Clinical Research', Health Affairs 19: 129-46.
121. Rochon, P., J.H. Gurwitz, R.W. Simms, P.R Fortin, D.T. Felson et al. (1994) 'A Study of Manufacturer-Supported Trials of Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Arthritis', Archives of Internal Medicine 154: 157-63.
122. Roman, Joanne (2002) 'U.S. Medical Research in the Developing World: Ignoring Nuremberg', Cornell Journal of Law and Public Policy 11: 441-60.
123. Roses, Allen D. (2001) 'Pharmacogenetics', Human Molecular Genetics 10(20): 2261-67.
124. Ryan, Michael (1998) Knowledge Diplomacy (Washington, DC: Brookings).
125. Scherer, F.M. (2002) 'The Economics of Human Gene Patents', Academic Medicine 77:1348-67.
126. Schulman, Kevin, D.M. Seils, J.W. Timbie, J. Sugarman, L.A. Dame et al. (2002) 'A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors', New England Journal of Medicine 347: 1335-41.
127. Sell, Susan (2003) Private Power, Public Law: The Globalization of Intellectual Property Rights (NewYork: Cambridge University Press).
128. Shah, Sonia (2003) 'Globalization of Clinical Research by the Pharmaceutical Industry', International Journal of Health Services 33: 29-36.
129. Shapin, Steven (2003) 'Ivory Trade', London Review of Books (11 September): 15-19.
130. Sharma, B.L. (2003) 'Indian Drug Institute Uses Computers to Reduce Animal Testing', Associated Press Worldstream (25 July). Available at 〈www.siliconvalley.com/mld/siliconvalley/6389346.htm?template= contentModules/printstory.jsp〉 (accessed 18 March 2005).
131. Siegel, Marc (2002) 'The Hungry Physician', Nation (30 December). Available at 〈www.thenation.com.doc.mhtml?I=20021230&S=siegal〉.
132. Smith, Richard (2003) 'Medical Journals and Pharmaceutical Companies: Uneasy Bedfellows', British Medical Journal 326: 1202-05.
133. Stelfox, H., G. Chua, K. O'Rourke & A.S. Detsky (1998) 'Conflict of Interest in the Debate over Calcium-Channel Antagonists', New England Journal of Medicine 338: 101-06.
134. Stephens, Joseph (2000) 'As Drug Testing Spreads, Profits and Lives Hang in Balance' (first of six-part series), Washington Post (17 December).
135. Stone, T. Howard (2003) 'The Invisible Vulnerable: Economically and Educationally Disadvantaged Subjects of Clinical Research', Currents in Contemporary Ethics 31(1): 149-53.
136. Streitz, Wendy D., Isabelle de Bear, Caroline S. Calmettes & Fred Reinhart (2003) 'Material Transfer Agreements: A Win-Win for Academia and Industry' (Power Point presentation), 〈www.autm.net〉.
137. Thursby, Jerry & M. Thursby (2003) 'University Licensing and the Bayh-Dole Act', Science 301: 1052.
138. Tilney, N.L. (2003) 'The Commercialization of Transplantation', Transplantation Proceedings 35: 1235-37.
139. Walsh, John, Ashish Arora & Wesley Cohen (2003) 'Research Tool Patenting and Licensing and Biomedical Innovation', in W. Cohen & S. Merrill (eds), Patents in the Knowledge-Based Economy (Washington, DC: National Academies Press): 285-340.
140. Wazana, Ashley (2000) 'Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?', Journal of the American Medical Association 283: 373.
141. Wilson, Duff & David Heath (2001) 'The Hutch Zealously Guards its Secrets', Seattle Times, 〈http://seattletimes.nwsource.com/uninformed_consent〉 (accessed 18 March 2005).
142. Yank, Veronica & Drummond Rennie (1999) 'Disclosure of Researcher Contributions', Annals of Internal Medicine 130: 661-70.
143. Zuckerman, Diana (2002) 'Hype in Health Reporting: Checkbook Science Buys Distortion of Medical News', Extra! (September/October).